Effect of Long-Term Exposure to Lower LDL Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease

This influential genetic study quantified something that reshapes how we should think about cholesterol treatment: lowering LDL early in life is far more powerful than lowering it later.

Using genetic variants that confer modestly lower lifelong LDL across more than 300,000 people, Ference and colleagues found that each 1 mmol/L of lifelong lower LDL was associated with a 54 percent reduction in coronary disease — roughly three times the benefit per unit that statins deliver when started in middle age (about 24 percent). The relationship was log-linear and consistent. Decades of slightly lower LDL compound into protection that late treatment cannot match.

The implication is profound and practical: cholesterol’s harm is cumulative, and the timing of lowering matters as much as the amount. It is a central piece of the case for earlier, not just harder, intervention.

We rate the evidence strong. As a large Mendelian randomization analysis it carries causal weight, and together with the Domanski exposure data it forms the backbone of the “lower, earlier, for longer” understanding of LDL.